AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20448192 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 100
Study 20448192 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 100
Study 22301207 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine (0.5, 1.0, or 1.5 mg/kg) with midazolam (0.03 mg/kg)
Number of subjects: 96
Study 22301207 — intervention group
Group type: COMPARATOR
Intervention: IV lidocaine (0.5, 1.0, or 1.5 mg/kg) with placebo
Number of subjects: 96
Study 15556966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning (10 min at 4 vol%)
Number of subjects: 72
Study 15556966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15556966 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane preconditioning
Number of subjects: 72
Study 12466788 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dipyridamole infusion (0.70 mg/kg) followed by technetium 99m tetrofosmin (TF) injection (74 to 370 MBq)
Number of subjects: 106
Study 12466788 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 age-matched patients without heart disease)
Number of subjects: 106
Study 9568451 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (16 weeks)
Number of subjects: 134
Study 9568451 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (6 weeks)
Number of subjects: 134
Study 9568451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer with calisthenic exercises
Number of subjects: 134
Study 9568451 — intervention group
Group type: COMPARATOR
Intervention: Cycle ergometer alone
Number of subjects: 134
Study 7855555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (CP) 8 mg/kg/d b.i.d.
Number of subjects: 260
Study 7855555 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (ACA) 40/10 mg/kg/d t.i.d.
Number of subjects: 260
Study 2642671 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise training for six months
Number of subjects: 16
Study 2642671 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy for six months
Number of subjects: 16
Study 4908340 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol administration of influenza vaccine
Number of subjects: 2100
Study 4908340 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of A2/Hong Kong/68 virus vaccine
Number of subjects: 2100
Study 4908340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent (A2 and B) influenza virus vaccine
Number of subjects: 2100
Study 4908340 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose immunization
Number of subjects: 2100
Study 4908340 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose immunization
Number of subjects: 2100
Study 4908340 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 2100
Study 29239901 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antiretroviral therapy (mART)
Number of subjects: 2431
Study 29239901 — intervention group
Group type: COMPARATOR
Intervention: Infant nevirapine (iNVP) prophylaxis
Number of subjects: 2431
Study 29239901 — intervention group
Group type: EXPERIMENTAL
Intervention: mART
Number of subjects: 2431
Study 29239901 — intervention group
Group type: COMPARATOR
Intervention: iNVP
Number of subjects: 2431
Study 27981743 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) 50 g
Number of subjects: 56
Study 27981743 — intervention group
Group type: COMPARATOR
Intervention: Soy protein isolate (SPI) 50 g
Number of subjects: 56
Study 25311146 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.3 μg.kg(‐1)
Number of subjects: 120
Study 25311146 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1 mg.kg(‐1)
Number of subjects: 120
Study 25311146 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (control)
Number of subjects: 120
Study 24024321 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Hegu (LI 4)
Number of subjects: 90
Study 24024321 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine oocyte retrieval)
Number of subjects: 90
Study 24024321 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo needles)
Number of subjects: 90
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 100 mg once daily (QD) for 7 days
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 200 mg QD for 7 days
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 400 mg QD for 7 days
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 400 mg twice a day for 7 days
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 800 mg QD for 7 days
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 400 mg dose of FV-100
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg QD dosing regimen for 7 days in elderly subjects
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100 (all doses)
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal effect on FV-100
Number of subjects: 59
Study 21444712 — intervention group
Group type: EXPERIMENTAL
Intervention: FV-100
Number of subjects: 59
Study 18192843 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine tabs
Number of subjects: 20
Study 18192843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16455186 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg enteric‐coated tablet
Number of subjects: 26
Study 16455186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12802644 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of cefotaxime (Group A)
Number of subjects: 92
Study 12802644 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (Group B)
Number of subjects: 92
Study 10905488 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I treatment (40 microg x kg(‐1) x day(‐1))
Number of subjects: 12
Study 10905488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8621136 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulinlike growth factor I (IGF‐I)
Number of subjects: 337
Study 8621136 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulinlike growth factor binding protein 3 (IGFBP‐3)
Number of subjects: 337
Study 1417188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus partial ileal bypass surgery
Number of subjects: 78
Study 1417188 — intervention group
Group type: COMPARATOR
Intervention: Diet-control group
Number of subjects: 78
Study 3899841 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 248
Study 3899841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 30741682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral amyloid-β (Aβ) deposition measured by 11C Pittsburgh compound B (PIB) PET scan
Number of subjects: 30
Study 29626614 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) intervention (3.6‐11.6 g), 3 times per week for 6 months
Number of subjects: 51
Study 29626614 — intervention group
Group type: COMPARATOR
Intervention: Swimming training only (Control group)
Number of subjects: 51
Study 26250477 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + DL (scaling, root planing and laser irradiation of periodontal pockets)
Number of subjects: 32
Study 26250477 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 32
Study 24984928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate (Group 1)
Number of subjects: 60
Study 24984928 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine with epinephrine (Group 2)
Number of subjects: 60
Study 24984928 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group 3)
Number of subjects: 60
Study 22326721 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI without biofilm accumulation
Number of subjects: 10
Study 22326721 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI with biofilm accumulation
Number of subjects: 10
Study 22326721 — intervention group
Group type: EXPERIMENTAL
Intervention: CR without biofilm accumulation
Number of subjects: 10
Study 22326721 — intervention group
Group type: EXPERIMENTAL
Intervention: CR with biofilm accumulation
Number of subjects: 10
Study 20213467 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS (16 cmH2O) + PEEP (5 cmH2O)
Number of subjects: 21
Study 20213467 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 21
Study 18394965 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial sonography (TCS)
Number of subjects: 60
Study 16521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CHOv) solution (7 mL/kg) ingested at 0 and 45 min
Number of subjects: 12
Study 16521847 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte (CHOf) solution (7 mL/kg) ingested in smaller volumes at 0, 15, 30, 45, 60, and 75 min
Number of subjects: 12
Study 16521847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) solution (7 mL/kg) ingested at 0 and 45 min
Number of subjects: 12
Study 11867969 — intervention group
Group type: EXPERIMENTAL
Intervention: Avena sativa extract
Number of subjects: 12
Study 11867969 — intervention group
Group type: EXPERIMENTAL
Intervention: Avena Rhealba extract
Number of subjects: 12
Study 11867969 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (petrolatum ointment)
Number of subjects: 12
Study 11867969 — intervention group
Group type: COMPARATOR
Intervention: Untreated site
Number of subjects: 12
Study 10468696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 1 mg b.d.
Number of subjects: 370
Study 10468696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 2 mg b.d.
Number of subjects: 370
Study 10468696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 4 mg b.d.
Number of subjects: 370
Study 10468696 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron 8 mg b.d.
Number of subjects: 370
Study 10468696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 7784854 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate written consent from parents
Number of subjects: 517
Study 7784854 — intervention group
Group type: COMPARATOR
Intervention: Delayed response (after reminders) from parents
Number of subjects: 517
Study 1693087 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated display of transformations
Number of subjects: 108
Study 1693087 — intervention group
Group type: COMPARATOR
Intervention: Diagram sheet (Control Group 1)
Number of subjects: 108
Study 1693087 — intervention group
Group type: COMPARATOR
Intervention: Computer-presented display with ten discrete stages (Control Group 2)
Number of subjects: 108
Study 345889 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline preparation
Number of subjects: 16
Study 345889 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 31101570 — intervention group
Group type: COMPARATOR
Intervention: MCO plans for prostate only
Number of subjects: 66
Study 31101570 — intervention group
Group type: COMPARATOR
Intervention: MCO plans for whole pelvis
Number of subjects: 66
Study 31101570 — intervention group
Group type: COMPARATOR
Intervention: MCO plans for lung
Number of subjects: 66
Study 31101570 — intervention group
Group type: COMPARATOR
Intervention: MCO plans for pancreas
Number of subjects: 66
Study 31101570 — intervention group
Group type: COMPARATOR
Intervention: MCO plans for head and neck
Number of subjects: 66
Study 30739369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gaseous ozone applied into periodontal pockets twice a week for 2 weeks during active periodontal therapy
Number of subjects: 36
Study 30739369 — intervention group
Group type: COMPARATOR
Intervention: Control sites (no ozone therapy)
Number of subjects: 36
Study 29029258 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 76
Study 29029258 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Acupuncture
Number of subjects: 76
Study 25370147 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU/1 mL)
Number of subjects: 30
Study 25370147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24835171 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg orally)
Number of subjects: 0
Study 24835171 — intervention group
Group type: COMPARATOR
Intervention: Control experiments
Number of subjects: 0
Study 22713551 — intervention group
Group type: EXPERIMENTAL
Intervention: CaP-hybridized tendon graft
Number of subjects: 64
Study 22713551 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 64
Study 19635648 — intervention group
Group type: EXPERIMENTAL
Intervention: Inability to stop smoking
Number of subjects: 367
Study 17613399 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab (20 mg on Day 0 and Day 4)
Number of subjects: 80
Study 17613399 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG, 2.5 mg/kg/day for 3 to 5 days)
Number of subjects: 80
Study 17613399 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 80
Study 17613399 — intervention group
Group type: COMPARATOR
Intervention: Anti-thymocyte globulin (ATG)
Number of subjects: 80
Study 15255444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 26
Study 15255444 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 26
Study 12389081 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 376
Study 12389081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 9438629 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPP
Number of subjects: 115
Study 9438629 — intervention group
Group type: COMPARATOR
Intervention: IPOM
Number of subjects: 115
Study 8130287 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physical therapy (weekly for 9 months)
Number of subjects: 144
Study 8130287 — intervention group
Group type: COMPARATOR
Intervention: Home exercises (unsupervised)
Number of subjects: 144
Study 2446574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high doses to achieve plasma concentrations of more than 150 kallikrein inactivator units per milliliter)
Number of subjects: 11
Study 2446574 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 11
Study 2446574 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 11
Study 31209158 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program with physician training, assessment, and feedback; intervention details include didactic instruction and video vignettes modeling effective communication.
Number of subjects: 77
Study 31209158 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control arm; no specific intervention mentioned.
Number of subjects: 77
Study 31209158 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) program (excluding physicians with poor data quality).
Number of subjects: 77
Study 29619453 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exposure to one standard erythemal dose (SED; 100 J m‐2) of solar UV radiation three days per week for three weeks
Number of subjects: 36
Study 29619453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supervised sun exposure)
Number of subjects: 36
Study 29619453 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exposure to solar UV radiation
Number of subjects: 36
Study 26952713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 321
Study 25033585 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of fixed orthodontic appliances (Group A)
Number of subjects: 33
Study 25033585 — intervention group
Group type: COMPARATOR
Intervention: Removal of fixed orthodontic appliances (Group B)
Number of subjects: 33
Study 22054904 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar hemostasis
Number of subjects: 113
Study 22054904 — intervention group
Group type: COMPARATOR
Intervention: Bipolar hemostasis
Number of subjects: 113
Study 20199828 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-protein supplements (40 g of protein and 400 kcal per day)
Number of subjects: 60
Study 20199828 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 17469678 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer disease-modifying approaches such as immunotherapy
Number of subjects: 0
Study 17469678 — intervention group
Group type: EXPERIMENTAL
Intervention: Research participation
Number of subjects: 0
Study 15670038 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 98
Study 15670038 — intervention group
Group type: EXPERIMENTAL
Intervention: eptifibatide
Number of subjects: 98
Study 15670038 — intervention group
Group type: COMPARATOR
Intervention: no GPIIb-IIIa antagonist (control)
Number of subjects: 98
Study 14959726 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management education programs for children with asthma
Number of subjects: 0
Study 11034258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (0.3 mg/m2)
Number of subjects: 45
Study 11034258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (1 mg/m2)
Number of subjects: 45
Study 11034258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (3 mg/m2)
Number of subjects: 45
Study 11034258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (5 mg/m2)
Number of subjects: 45
Study 11034258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (8 mg/m2)
Number of subjects: 45
Study 11034258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 11034258 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 45
Study 8883008 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment in Frontal Plane (FP) for shoulder internal rotation (IR) and external rotation (ER)
Number of subjects: 20
Study 8883008 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment in Scapular Plane (SP) for shoulder internal rotation (IR) and external rotation (ER)
Number of subjects: 20
Study 1606397 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine
Number of subjects: 10
Study 4022696 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion
Number of subjects: 8
Study 4022696 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 8
Study 4022696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study 3675055 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (1 day)
Number of subjects: 120
Study 3675055 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (5 days)
Number of subjects: 120
Study 31769897 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-doxycycline
Number of subjects: 240
Study 31769897 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-rifampin
Number of subjects: 240
Study 31769897 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 240
Study 31184810 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive score model for mortality risk in dementia patients
Number of subjects: 6556
Study 27741216 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + CR
Number of subjects: 126
Study 27741216 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 126
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (OMP)
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol with sequential OMP
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: P4 (progesterone)
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol/OMP
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/E/E2+cyclic OMP at 200 mg/day
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/E/E2+MPA
Number of subjects: 0
Study 26512775 — intervention group
Group type: EXPERIMENTAL
Intervention: OMP with conjugated equine estrogen (CEE)/estrogen (E)/E2
Number of subjects: 0
Study 23796316 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic rehabilitation
Number of subjects: 195
Study 23796316 — intervention group
Group type: COMPARATOR
Intervention: General practitioner (GP) treatment as usual
Number of subjects: 195
Study 22403989 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Pro‐Relief (8.0% arginine, calcium carbonate, 1450 ppm fluoride)
Number of subjects: 121
Study 22403989 — intervention group
Group type: COMPARATOR
Intervention: Sensodyne Rapid Relief (8% strontium acetate, 1040 ppm fluoride)
Number of subjects: 121
Study 19375907 — intervention group
Group type: EXPERIMENTAL
Intervention: Older men
Number of subjects: 4198
Study 19375907 — intervention group
Group type: COMPARATOR
Intervention: Men with a family history of prostate cancer
Number of subjects: 4198
Study 19375907 — intervention group
Group type: COMPARATOR
Intervention: Men with raised PSA of 10-<20ng/ml
Number of subjects: 4198
Study 19375907 — intervention group
Group type: COMPARATOR
Intervention: Change in anxiety scores since the initial PSA test
Number of subjects: 4198
Study 16808019 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional up-dosing treatment schedule
Number of subjects: 20
Study 16808019 — intervention group
Group type: COMPARATOR
Intervention: No-up-dosing treatment schedule
Number of subjects: 20
Study 16646877 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Music-making (RMM) protocol, 6 sessions focusing on group support and stress reduction
Number of subjects: 75